Dexcom (DXCM) stock: key figures, P/E, revenue and dividend

Health Care · Health Care Equipment · United States · ISIN US2521311074

Price
83.47 USD
Market cap
31.50 bn USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

Dexcom financials

Fiscal year2025
Revenue4.66 bn USD
Gross profit2.80 bn USD
Operating income911.80 m USD
EBIT994.00 m USD
Net income836.30 m USD
Diluted EPS – continuing operations2.09 USD

Full history since 2000, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Dexcom

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.

Dexcom stock (DXCM): P/E, revenue, dividend | finmetric